VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS

9 Months Ended

Sep. 30, 2023

Equity Method Investments and Joint Ventures [Abstract]

VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS

Venture capital investments are summarized below:


	Nine Months Ended
	September 30, 2023		September 24, 2022
	(in thousands)
Beginning balance	$	129,012	$	149,640
Capital contributions	12,056		11,815
Distributions	(12,972)		(7,733)
Losses	(14,258)		(20,063)
Foreign currency translation	260		(2,149)
Ending balance	$	114,098	$	131,510

The Company also invests, with minority positions, directly in equity of predominantly privately held companies. Strategic investments are summarized below:


	Nine Months Ended
	September 30, 2023		September 24, 2022
	(in thousands)
Beginning balance	$	182,590	$	51,712
Purchase of investments	21,489		117,220
Distributions	(7,493)		(1,710)
Gain (loss)	5,012		(5)
Reduction for acquisition of entity	(12,635)		—
Foreign currency translation	(1,214)		(8,636)
Ending balance	$	187,749	$	158,581

In April 2022, the Company acquired a 49% equity interest in a supplier supporting the DSA reportable segment (the Investee) for $90.0 million up front and an additional future contingent payment of up to $5.0 million based upon the Investee’s future performance. In August 2023, a contingent payment of $2.5 million was made to the Investee, with an additional $2.5 million to be earned based on future performance. The total allocable basis of the investment exceeded the proportional interest in the Investee’s underlying net assets by $86.7 million, which has been allocated primarily to goodwill, intangible assets (client relationships and backlog), and deferred tax liabilities in the amount of $26.2 million, $71.2 million, and $10.7 million respectively. On July 28, 2023, the Company signed an agreement to acquire an additional 41% equity stake in the supplier, which upon closing, will result in ownership of 90%. The preliminary purchase price for the 41% equity is $143 million in cash, subject to customary closing adjustments, with additional contingent payments of up to $55 million based on future performance over a 3-year period. The Company will have the call option right to purchase the remaining 10% equity up until one month after the sixth anniversary of closing. On the first anniversary of the expiration of the call option, a 12-month put option will be triggered giving the seller the right to require the Company to acquire shares of the Investee from the seller. The consummation of the acquisition of the additional 41% equity is subject to regulatory approval and closing conditions being satisfied. Accordingly, the timing of close is uncertain.